As a leading company in the field of radiological applications in medical treatment Nihon Medi-Physics aims to offer our technical know-how and accumulated knowledge to progress the field of medical care while challenging the technical development of nuclear medicine through close collaboration with related academic and research institutes. Nihon Medi-Physics will contribute toward meeting unmet medical needs and solving various kinds of medical challenges by widely enhancing public awareness about the potentials and possibilities of nuclear medicine in Japan through the application of our technology.
Drug Discovery
Leveraging the unique properties of radiopharmaceuticals that can visualize changes and reactions occurring at the molecular level in the body (molecular imaging), we are developing applications of the technology in new areas. These include the use of visualization to diagnose previously difficult-to-diagnose cancers and the clarification of the pathology of dementia by imaging suspected causative substances. Additionally, in the context of theranostics, which has attracted worldwide attention in recent years, we are engaged in research on the production of the α-particle-emitting nuclides to be used as therapeutic radioisotopes, as well as drug discovery research using these nuclides.
Drug Discovery Bases
As our central drug discovery base, the Research Center is engaged in the research and development of radiopharmaceuticals, their commercialization, and product improvement studies.
Research Center
Completed in 2019 to commercially realize theranostics, this drug discovery base is engaged in the research and development of radioactive therapeutics and diagnostics, as well as the manufacture and shipment of investigational drugs.
CRADLE Facility
αSTARTZ
Based on our proprietary technology, we can site-specifically label a variety of molecules, including antibodies that bind specifically to tumor antigens, with actinium-225 for therapeutic use and zirconium-89 for diagnostic use. Currently, we are conducting research and development into targeted α-particle therapeutics using this technology.
αSTARTZ：225Ac-α Site Targeting Advanced Radioisotope Treatment via 89Zr-CDx
Contract Business
We are engaged in contract services for conducting non-clinical PET imaging studies and manufacturing investigational drugs for use in RI clinical trials so that pharmaceutical companies and academia can conduct their drug discovery activities using the technology we have cultivated through our in-house radiopharmaceutical development. In addition to using our unique technology to contribute broadly to pharmaceutical development, we are positioning our contract services as an important activity that will lead to the development of nuclear medicine in the future.
Intellectual Property Strategy
We recognize the importance of intellectual property rights in the contexts of pharmaceuticals and medical devices. While respecting the rights of others, we strategically acquire and maintain intellectual property rights to protect the technologies and products we develop. Additionally, we proactively apply for and obtain patents and relevant rights for inventions achieved in collaboration with external research institutions. For product protection, we are building a patent portfolio that includes not only substance patents but also related patent applications for uses, manufacturing methods, formulations, and image processing software, among others. Furthermore, we utilize design rights and trademark rights to promote multifaceted product protection. We have also established regulations regarding employee inventions and strive to encourage activities for intellectual creativity within the company.
